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To the Editor,
Fibromyalgia syndrome (FMS) is a complex illness to diag-
nose and treat, which presents symptoms that may be part 
of, or overlap with other diseases or syndromes.
The most widely used diagnostic criteria are those of 
the American College of Rheumatology [1]; no laboratory 
test has been validated for FMS diagnosis which remains 
primarily clinically based.
Oxidative stress has been proposed as a relevant 
event in the pathogenesis of FMS with an increase of lipid 
peroxidation (LPO) [2] and a decrease in vitamin A and E 
concentrations [3].
Although the etiology of FMS remains unclear, genetic 
predisposition is likely to be an important factor and 
transmission is thought to be polygenic [4, 5]. If FMS is a 
multi-genetic disease then it could be hypothesized that 
differences exist in the type of proteins or protein expres-
sion levels in sera of FMS patients compared with healthy 
controls.
Proteomic analysis is a powerful tool for the global 
evaluation of protein expression and plays a central role 
in clinical diagnosis and monitoring. Some studies [6] 
reported interesting proteomic analysis data with an over-
expression of transaldolase and phosphoglicerate mutase 
I in salivary fluid of FMS patients and focused on the role 
of oxidative stress in the pathogenesis of the disease.
The aim of this preliminary study was to evaluate, 
using two-dimensional gel electrophoresis (2-DE) and 
mass spectrometry (MS), changes in protein profiles of 
FMS patients with respect to control subjects to identify 
potential serum biomarkers useful for disease diagnosis 
and management.
Sixteen females (52 ± 12 years) affected by FMS and 12 
healthy females (48 ± 13 years) were enrolled; all patients 
fulfilled new ACR diagnostic criteria [1] (Table 1). The pres-
ence of a major clinical condition other than fibromyalgia 
was excluded by physical examination and routine blood 
and urine screening. No patients suffered of thyroid dys-
function. Psychiatric examination data of patients were 
reported in a previous study [7].
Study was approved from our Local Ethical Commit-
tee and informed consent was obtained from all subjects.
Serum protein concentrations were quantified using 
the PlusOne 2D Quant Kit (GE Healthcare); first dimen-
sion isoelectric focusing (IEF) was carried out with 18 cm 
immobilized pH gradient strips of pH 3–10. The IPG strips 
were applied onto 10% acrylamide sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) slab gels 
(25.5 cm × 20.5 cm × 1.0 mm) and overlaid with a solution of 
0.5% agarose with a trace of bromophenol blue. Gels were 
fixed, stained with Coomassie Brilliant Blue G-250 colloi-
dal for 24 h and stored at room temperature. At least three 
sample replicates were performed.
2D data were processed with Progenesis SameSpots 
software, which computed multiplication fold, false dis-
covery rate (FDR) q-value, p-values of all spots using 
one-way ANOVA analysis. A p-value  < 0.05 was considered 
statistically significant; no difference has been found in 
protein expression according to patient therapy.
After normalization, volume calculation and statisti-
cal analysis, same data differences were observed between 
*Corresponding author: Dr. Antonella Fais, Dipartimento di Scienze 
della Vita e dell’Ambiente, Università di Cagliari, 09042 Monserrato, 
Cagliari, Italy, Phone: +39 0706754506, Fax: +39 0706754523, 
E-mail: fais@unica.it
Valeria Ruggiero and Enrico Cacace: Dipartimento di Scienze Mediche 
“Mario Aresu”, Università di Cagliari, Monserrato, Cagliari, Italy
Benedetta Era, Marcella Corda and Stefania Utzeri: Dipartimento 
di Scienze della Vita e dell’Ambiente, Università di Cagliari, 
Monserrato, Cagliari, Italy
Laura Molin: CNR-ISTM, Corso Stati Uniti 4, Padova, Italy
Brought to you by | Universita degli Studi di Cagliari
Authenticated
Download Date | 9/30/14 10:34 AM
e208      Ruggiero et al.: Proteomic in fibromyalgia syndrome
Table 1 Characteristics and scores of the patients and healthy controls examined subjects.
  FMS (n = 16)  HC (n = 12)
Age, years (mean (SD), range)   52 ± 12 (27–72)  48 ± 13 (27–67)
Sex   Females  Females
Menopause   n = 10  n = 5
Body mass index, m2/kg (mean ± SD)   27 ± 5  24 ± 3
Duration, month from diagnosis of the disease, mean ± SD   6.3 ± 4.5  –
Pain duration, years (mean ± SD)   4.9 ± 0.5  –
Pain score patient VAS, mm (mean ± SD)   57 ± 31  –
Pain score physician VAS, mm (mean ± SD)   34 ± 18  –
FIQ total score, 0–80 (mean ± SD)   61.8 ± 21.9  –
Associated clinical distresses
 Tension type headache   n = 12  –
 Irritable colon   n = 9  –
 Oto vestibule syndrome   n = 9  –
 Paraesthesia   n = 8  –
 Sleep disturbance   n = 8  –
 Dysmenorrhea   n = 2  –
 Hemicrania   n = 4  –
 Urethral syndrome   n = 5  –
Medication
 No therapy   n = 5  n = 12
 Tricyclic, Amitriptyline  < 15 mg/day   n = 6  –
 Selective serotonin reuptake inhibitors (SSRIs) (Citalopram)   n = 1  –
 Selective Serotonin Noradrenaline Reuptake Inhibitors (SSNRIs) (Duloxetin)  n = 4  –
FIQ, FMS impact questionnaire; VAS, visual analogue scale.
Table 2 Identification of 2D-separated proteins. 
Spot 
ID
  Method   Short 
name
  Accession 
no.
  MW, 
kDA
  pI   Score  Coverage, 
%
  p-Value   Fold-
increase
  Sequence
106  MS   AAT   P01009   46  5.37  91  51  3.228e-005  2.0  K.LVDKFLEDVKK.L
                    K.VFSNGADLSGVTEEAPLK.L
                    K.VFSNGADLSGVTEEAPLKLSK.A
                    K.GKWERPFEVKDTEEEDFHVDQVTTVK.V
1065  MS   TTR   P02766   15  5.52  121  100  0.007  1.3  K.AADDTWEPFASGK.T
                    R.KAADDTWEPFASGK.T
                    K.ALGISPFHEHAEVVFTANDSGPR.R
                    K.ALGISPFHEHAEVVFTANDSGPRR.Y
                    K.TSESGELHGLTTEEEFVEGIYKVEEIDTK.S
2334  MS/MS   RBP4   P02753   23  5.8  70  12  0.039  1.2  R.LIVHNGYCDGRSERNLL.N
                    K.GNDDHWIVDTDYDTYAVQYSCR.L
healthy subjects and patients. In particular, three statisti-
cally different spots (106, 1065 and 2334) were highlighted 
(Table 2) and the related proteins were subsequently iden-
tified by matrix-assisted laser desorption/ionization time-
of-flight (MALDI-TOF) and MS/MS.
Protein spots of interest were manually excised from 
2-DE gels following the procedure described and adapted 
by Shevchenko et al. [8]. Identification of proteins was per-
formed by peptide-mass fingerprint MALDI/MS measure-
ments using a MALDI-TOF/TOF UltrafleXtreme, equipped 
with 1 kHz smartbeam II laser (λ = 355 nm) and operating 
in the positive reflectron ion modes. The instrumental con-
ditions employed to analyze molecular weight in the m/z 
range 980–7000 were: Ion Source 1: 25.00 kV; Ion Source 2: 
22.40 kV, Lens: 8.00 kV, Reflector: 26.45 kV, Reflector 2: 13.45 
kV, Pulsed ion extraction: 120 ns. The matrix employed 
was α-cyano-4-hydroxycinnamic acid (HCCA) (saturated 
solution in H2O/Acetonitrile (50:50; v/v) containing 0.1% 
trifluoroacetic acid (TFA). External mass calibration was 
performed using the Peptide Calibration Standard, based 
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on the monoisotopic values of [M+H]+ of Angiotensin II, 
Angiotensin I, Substance P, Bombesin, ACTH clip (1-17), 
ACTH clip (18-39), Somatostatin 28 at m/z 1046.5420, 
1296.6853, 1347.7361, 1619.8230, 2093.0868, 2465.1990 and 
3147.4714, respectively. The peptide masses were searched 
against the National Center for Biotechnology Information 
non-redundant mammalian (Taxonomy homo sapiens) 
database using Mascot 2.3 searched from Matrix Science, 
selecting the Swiss-Prot database. For the present study, 
protein identification was based on measurements with a 
Mascot score higher than 55. Minimal expectation for valid 
identification was p < 0.005 and p < 0.05.
The spot ID106 is due to α1-antitrypsin (AAT), spot 
ID1065 to transthyretin (TTR) and spot ID2334 to retinol 
binding protein 4 (RBP4) (Mascot database). These iden-
tifications were confirmed by MS/MS experiments on 
selected peptides present in the tryptic digestion mixture 
of each spot.
Immunoprecipitation tests, carried out by auto-
mated immunochemistry analyzer, confirmed an increase 
of identified proteins. No correlation has been found 
between overexpressed proteins and duration of the 
disease, VAS or FIQ.
For the first time, in this preliminary study some dif-
ferences between the human serum protein pattern of FMS 
patients with respect to healthy controls have been found.
The most relevant result is a significant over-expres-
sion of three proteins identified by a proteomic approach: 
TTR, RBP4 and AAT in FMS patients.
Oxidative stress has been proposed as a relevant event 
in the pathogenesis of FMS [2]. A complex defence system 
protects against oxidative stress including enzymes and 
non-enzymatic species, such as vitamins C, E and A; 
vitamin A-bound RBP4 is associated to TTR.
Akkus et  al. [3] showed a reduction of vitamin A in 
FMS patients as a result of its role on radical inhibition 
and hypothesized an imbalance between ROS production 
and the antioxidant defence system in patients with fibro-
myalgia syndrome. These data might be consistent with a 
previous study [9] that showed unexpected normal levels 
of uric acid (despite high levels of inosine, hypoxanthine, 
xanthine) in FMS patients possibly as a result of its role as 
a ROS scavenger.
Our data show increased serum RBP4; upregulation 
of RBP4 may induce hypovitaminosis A [10].
High serum TTR and RBP4 might be a result of a 
flow out from the cells due to ROS-mediated alteration 
of membrane integrity or permeability; in fact, in vivo 
experiments have suggested that RBP4 also accumulates 
in vitamin A-deficient hepatocytes but is not secreted into 
the bloodstream [11].
In our study, an overexpression of serum AAT was 
also observed; Blanco and Coll reported high AAT plasma 
concentrations in a subset of FMS patients and a signifi-
cantly increased number of mast cells (MCs) in the pap-
illary dermis of all FMS patients with moderately high 
levels of AAT [12]. The mastocyte-released chemicals 
could cause local manifestations (e.g., skin tenderness or 
pain) that might be related to enhanced pain sensitivity of 
these patients.
A previous study [13] reported a slight increase of 
AAT associated with a decrease of vitamin A suggest-
ing that genetic or environmental factors may influence 
AAT activity, which is dependent on the antioxidant 
capacity of liposoluble vitamins. AAT can be oxidized 
by free radicals released from oxidative stress, result-
ing in protein dysfunction that leads to the imbalance 
between AAT and proteases, which can cause tissue 
damage [14]. Then there may be high levels of AAT (as 
reported in our study) but with ineffective action as pro-
tease inhibitor.
Considering that the TTR and RBP4 are both retinoid 
transporters, retinoid dysfunction is related to oxida-
tive stress as well as AAT. Furthermore, assessment of 
thiobarbituric acid reactive substances for the measure-
ment of lipid peroxidation revealed values over two-fold 
of the normal range in FMS patients (data not shown), 
indicating a condition of oxidative stress. These data 
are in agreement with previous studies that underline 
the involvement of oxidative stress in the pathology of 
FMS. Additional studies are required to clarify their exact 
relationships.
Acknowledgments: We thank the patients and the healthy 
volunteers who participated in this study. The authors 
would like to thank the University of Vigo for the use of 
the Progenesis SameSpots software. This study was sup-
ported by the RAS–LR7/2007 [grant number CRP-24879] 
and University of Cagliari.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors 
stated that there are no conflicts of interest regarding the 
publication of this article. Research support played no 
role in the study design; in the collection, analysis, and 
interpretation of data; in the writing of the report; or in the 
decision to submit the report for publication.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Brought to you by | Universita degli Studi di Cagliari
Authenticated
Download Date | 9/30/14 10:34 AM
e210      Ruggiero et al.: Proteomic in fibromyalgia syndrome
References
1. Wolfe F, Clauw DJ, Fitzcharles M-A, Goldenberg DL, Katz RS, 
Mease P, et al. The American College of Rheumatology preliminary 
diagnostic criteria for fibromyalgia and measurement of symptom 
severity. Arthritis Care Res (Hoboken) 2010;62:600–10.
2. Castro-Marrero J, Cordero MD, Sáez-Francas N, Jimenez-
Gutierrez C, Aguilar-Montilla FJ, Aliste L, et al. Could 
mitochondrial dysfunction be a differentiating marker between 
chronic fatigue syndrome and fibromyalgia? Antioxid Redox 
Signal 2013;19:1855–60.
3. Akkus S, Nazıroğlu M, Eris S, Yalman K, Yılmaz N, Yener M.  
Levels of lipid peroxidation, nitric oxide, and antioxidant vitamins 
in plasma of patients with fibromyalgia. Cell Biochem Funct 
2009;27:181–5.
4. Buskila D, Sarzi-Puttini P, Ablin JN. The genetics of fibromyalgia 
syndrome. Pharmacogenomics 2007;8:67–74.
5. Cordero MD, Díaz-Parrado E, Carrión AM, Alfonsi S, Sánchez-
Alcazar JA, Bullón P, et al. Is inflammation a mitochondrial 
dysfunction-dependent event in fibromyalgia? Antioxid Redox 
Signal 2013;18:800–7.
6. Giacomelli C, Bazzichi L, Giusti L, Ciregia F, Baldini C, Da Valle Y, 
et al. MALDI-TOF e SELDI-TOF: due tecniche “tandem” per 
l’individuazione di potenziali biomarker nella fibromialgia. 
Reumatismo 2011;63:165–70.
7. Carta MG, Ruggiero V, Sancassiani F, Cutrano F, Manca AR, Peri M, 
et al. The use of antidepressants in the long-term treatment 
 should not improve the impact of fibromyalgia on quality of life. 
Clin Pract Epidemiol Ment Health 2013;9:120–4.
8. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric 
sequencing of proteins silver-stained polyacrylamide gels. Anal 
Chem 1996;68:850–8.
9. Fais A, Cacace E, Corda M, Era B, Peri M, Utzeri S, et al. 
Purine metabolites in fibromyalgia syndrome. Clin Biochem 
2013;46:37–9.
10. Chuang C-M, Chang C-H, Wang H-E, Chen K-C, Peng C-C, 
Hsieh C-L, et al. Valproic acid downregulates RBP44 and elicits 
hypervitaminosis A-teratogenesis—a kinetic analysis on retinol/
retinoic acid homeostatic system. PLoS One 2012;7:e43692.
11. Ronne H, Ocklind C, Wiman K, Rask L, Öbrink B, Peterson PA. 
Ligand-dependent regulation of intracellular protein transport: 
effect of vitamin a on the secretion of the retinol-binding 
protein. J Cell Biol 1983;96:907–10.
12. Blanco I, Béritze N, Argüelles M, Cárcaba V, Fernández F, 
Janciauskiene S, et al. Abnormal overexpression of mastocytes 
in skin biopsies of fibromyalgia patients. Clin Rheumatol 
2010;29:1403–12.
13. Marzatico F, Gaetani P, Tattara F, Bertorelli L, Feletti F, 
Adinolfi D, et al. Antioxidant status and α1-antiproteinase 
activity in subarachnoid hemorrhage patients. Life Sci 
1998;63:821–4.
14. Jamnongkan W, Techasen A, Thanan R, Duenngai K, 
Sithithaworn P, Mairiang E, et al. Oxidized alpha-1 antitrypsin as 
a predictive risk marker of opisthorchiasis-associated cholan-
giocarcinoma. Tumour Biol 2013;34:695–704.
Brought to you by | Universita degli Studi di Cagliari
Authenticated
Download Date | 9/30/14 10:34 AM
